Screening of Wound-Healing Agents

Definition, rationale & the biology being modelled

• Definition — Screening of wound-healing agents is the battery of standardised in vivo (rat/mouse) and in vitro assays used to detect and rank pro-healing (or anti-healing) activity of a test substance — herbal extract, growth factor, dressing or drug — against a validated reference standard.
• Experimentally, wound healing is quantified by the mechanical strength and closure kinetics the wound develops over time; a candidate drug's effect is inferred from how it shifts these time-course parameters against controls.
• Healing is a multiphasic, overlapping process — each phase supplies a distinct measurable endpoint:
  • Haemostasis — clot/platelet plug, provisional fibrin matrix (immediate).
  • Inflammatory phase — vasodilatation, increased permeability, leukocyte influx; PGE₂ and prostacyclin (PGI₂) are the primary prostanoid mediators (with histamine, bradykinin, 5-HT, LTs, PAF, TNF, IL-1).
  • Proliferative phase — fibroblast proliferation, angiogenesis, granulation-tissue deposition, collagen synthesis and re-epithelialisation.
  • Remodelling/maturation — collagen cross-linking & reorganisation → progressive gain in tensile (breaking) strength.
• Why three models in parallel — No single model captures all of healing, so the classic screen runs three complementary rat models — excision (contraction + epithelialisation), incision (tensile strength) and dead-space (granulation-tissue collagen) — with special models (burn, diabetic/steroid-impaired) probing adverse conditions.
• Pharmacological rationale for the controls — Prostanoid synthesis rises in injured tissue; because NSAIDs (COX inhibitors) and glucocorticoids modulate this inflammatory phase, anti-inflammatory drugs are the canonical accelerating or impairing control compounds against which new agents are benchmarked.